Wells Fargo announces a new $40 billion stock buyback program, reflecting its strong capital position and commitment to returning capital to shareholders.
Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded GLP-1 alternatives become less available.
Royal Caribbean's strong Q1 results and raised 2025 outlook driven by record bookings, robust demand, and lower costs.
Wells Fargo announces a new $40 billion stock buyback program, reflecting its strong capital position and commitment to returning capital to shareholders.
Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded GLP-1 alternatives become less available.
Royal Caribbean's strong Q1 results and raised 2025 outlook driven by record bookings, robust demand, and lower costs.